Stay updated on Durvalumab vs Placebo in Early NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab vs Placebo in Early NSCLC Clinical Trial page.

Latest updates to the Durvalumab vs Placebo in Early NSCLC Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.3.3 appears in the footer, and HHS Vulnerability Disclosure and Revision: v3.3.2 were removed. This is a minor site maintenance update that does not affect the study record history; to avoid alerts for small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedFooter revision updated from v3.2.0 to v3.3.2; no study data or navigation changes observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check37 days agoChange DetectedNew version entries were added on 2025-11-10 and 2025-11-07, including a new Study Status item. A government funding notice was removed (dated 2025-07-14). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check51 days agoChange DetectedNew history entries document additional study record updates (e.g., recruitment status and contacts/locations) on the Record History page. The overall page layout remains unchanged.SummaryDifference0.1%

- Check80 days agoChange DetectedAdded a government operating-status notice and a new version tag (v3.2.0); removed the old version tag (v3.1.0).SummaryDifference9%

- Check87 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.2%

Stay in the know with updates to Durvalumab vs Placebo in Early NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab vs Placebo in Early NSCLC Clinical Trial page.